Genotype-specific persistence of genital human papillomavirus (HPV) infections in women followed for 6 years in the finnish family HPV study

Journal of Infectious Diseases

Volumn 202, Issue 3, 2010, Pages 436-444

  Louvanto, Karolina ^a,b   Rintala, Marjut Anne ^b   Syrjänen, Kari Juhani ^c   Grénman, Seija Elisa ^b   Syrjänen, Stina Marita ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b Departments of Obstetrics and Gynecology   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CURETTAGE; DISEASE DURATION; DNA SCREENING; FAMILY HEALTH; FEMALE; FEMALE GENITAL TRACT INFECTION; FINLAND; FOLLOW UP; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 73; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; ORAL CONTRACEPTION; ORAL SEXUAL CONTACT; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PERSISTENT VIRUS INFECTION; PHYLOGENY; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUAL BEHAVIOR; SMOKING; THIRD TRIMESTER PREGNANCY; VIRUS GENE; WART VIRUS; CLASSIFICATION; COMORBIDITY; GENETICS; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; PAPILLOMA VIRUS; PREGNANCY; PREGNANCY COMPLICATION; RISK FACTOR; TIME; VIROLOGY;

ADULT; COMORBIDITY; DNA, VIRAL; FEMALE; FINLAND; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; RISK FACTORS; TIME FACTORS;

EID: 77954707647     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653826     Document Type: Article

References (41)

1. Zur Hausen H. Papillomaviruses causing cancer: evasion from hostcell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92(9):690-698.
2. De Villiers EM. Classification of papillomaviruses. Virology 2004; 324(1): 17-27.
3. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6):518-527. (Pubitemid 36159887)
4. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26(suppl 10):K1-K16.
5. Richardson H, Kelsall G, Tellier P, et al. The natural history, of typespecific human papillomavirus infection in female university students. Cancer Epidemiol Biomarkers Prev 2003; 12:485-490.
6. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of typespecific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1796-1807.
7. Gargiulo F, De Francesco MA, Schreiber C, et al. Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res 2007; 125(2): 176-182.
8. Bosch FX, de Sanjosé S. Human papillomavirus and cervical cancer- burden and assessment of causality. J Natl Cancer Inst Monogr 2003; (31):3-13.
9. Castle PE, Rodríguez AC, Burk RD, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009; 339:b2569.
10. Liaw KL, Hildeshaeim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183:8-15.
11. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337(1): 76-84.
12. Kulmala SM, Shabalova IP, Petrovitchev N, et al. Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study. Cancer Epidemiol Biomarkers Prev 2007; 16(1):17-22.
13. Trottier H, Mahmud S, Prado JC, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008; 197(10):1436-1447.
14. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-428.
15. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004; 73(1):65-70.
16. Castellsagué X, Bosch FX, Muñoz N. Environmental co-factors in HPV carcinogenesis. Virus Res 2002; 89(2):191-199.
17. Nielsen A, Kjaer SK, Munk C, Iftner T. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis 2008; 35(3): 276-282.
18. Rintala M, Puranen M, Isolauri E, et al. Transmission of high risk HPV between parents and infants: a prospective HPV Family Study in Finland. J Clin Microbiol 2005; 43(1):376-381.
19. Rintala MA, Grénman SE, Puranen MH, et al. Transmission of highrisk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland. J Clin Microbiol 2005; 43(1):376-381.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
21. Snijders PJF, van den Brule AJC, Schrijnemakers HFJ, Snow G, Meijer CJLM,Walboomers JMM. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 1990; 71:173-181.
22. Anttila M, Syrjänen S, Ji H, Saarikoski S, Syrjänen K. Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR. Gynecol Oncol 1999; 72:337-341.
23. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006; 44(2):504-512.
24. Diggle PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data, first ed. Oxford: Oxford University Press, 1994.
25. Hardin J, Hilbe JM. Generalized estimating equations. Boca Raton, FL: Chapman & Hall, 2003.
26. Nielsen A, Kjaer SK, Munk C, Olster M, Ifner T. Persistence of high risk human papillomavirus infection in a population-based cohort of Danish women, J Med Virol 2010; 82(4):616-623.
27. Ralston Howe E, Li Z, McGlennen RC, Hellerstedt WL, Downs LS Jr. Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening. Am J Obstet Gynecol 2009; 200(3): 245.e1-e7.
28. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, WheelerCM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582-1589.
29. Syrjänen S, Shabalova I, Petrovichev N, et al. Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the former Soviet Union. Eur J Gynaecol Oncol 2005; 26:491-498. (Pubitemid 41585929)
30. Chen W, Zhang X, Molijn A, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009; 20(9):1705-1713.
31. Brandão Vda C, Lacerda HR, Lucena-Silva N, Ximenes RA. Frequency and types of human papillomavirus among pregnant and non-pregnant women with human immunodeficiency virus infection in Recife determined by genotyping. Mem Inst Oswaldo Cruz 2009; 104(5): 755-763.
32. Syrjänen KJ, Kulmala S-M, Shabalova IP, et al. Epidemiological, clinical and viral determinants of the increased prevalence of high-risk human papillomavirus (HPV) infections in elderly women. Eur J Gynaecol Oncol 2008; 29:114-122.
33. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370(9599):1609-1621.
34. Moreno V, Bosch FX, Muñoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359(9312): 1085-1092.
35. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 1996; 93(7):2930-2935.
36. Richardson H, Abrahamowicz M, Tellier PP, et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005; 14(5):1149-1156.
37. Poppe W, Ide P, Drijkoningen M, Lauweryns J, Van Assche F. Tobacco smoking impairs the local immunosurveillance in the uterine cervix: an immunohistochemical study. Gynecol Obstet Invest 1995; 39:34-38.
38. Simen-Kapeu A, Kataja V, Yliskoski M, et al. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection. Scand J Infect Dis 2008; 40(9):745-751.
39. Rintala M, Grénman S, Puranen M, Syrjänen S. Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPVFamily Study. J Clin Virol 2006; 35(1):89-94.
40. Sarkola ME, Grénman SE, Rintala MA, Syrjanen KJ, Syrjanen SM. Effect of second pregnancy on maternal carriage and outcome of highrisk human papillomavirus (HPV): experience from the prospective finnish family HPV study. Gynecol Obstet Invest 2009; 67(3):208-216.
41. Syrjänen S, Waterboer T, Sarkola M, et al. Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol 2009; 90(Pt 6):1515-1526.